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Abstract: Postoperative Ileus (POI) is a frequent, frustrating occurrence for patients and 
surgeons after abdominal surgery. Despite signiﬁ  cant research investigating how to reduce this 
multi-factorial phenomenon, a single strategy has not been shown to reduce POI’s signiﬁ  cant 
effects on length of stay (LOS) and hospital costs. Perhaps the most signiﬁ  cant cause of POI is 
the use of narcotics for analgesia. Strategies that target inﬂ  ammation and pain reduction such as 
NSAID use, epidural analgesia, and laparoscopic techniques will reduce POI but are accompanied 
by a simultaneous reduction in opioid use. Pharmacologic means of stimulating gut motility have 
not shown a positive effect, and the routine use of nasogastric tubes only increases morbidity. 
Recent multi-site phase III trials with alvimopan, a peripherally acting mu-antagonist, have 
shown signiﬁ  cant reductions in POI and LOS by 12 and 16 hours, respectively, by blunting the 
effects of narcotics on gut motility while sparing centrally mediated analgesia. Use of alvimopan, 
along with a multi-modal postoperative treatment plan involving early ambulation, feeding, and 
avoiding nasogastric tubes, will likely be the crux of POI treatment and prevention.
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Introduction
Despite numerous advances in surgical technique and perioperative care, postoperative 
ileus (POI) continues to be one of the most common and expected aspects of abdominal 
surgery. It prolongs hospital stays, increases medical costs and frustrates patients and 
surgeons (Schuster et al 2006; Viscusi et al 2006). Many authors suggest that POI is a 
mandatory phase of the recovery period for any intra-abdominal procedure, and only 
an ileus lasting greater than 5 days is abnormal – to be termed a prolonged POI (Holke 
and Kehlet 2000; Delaney 2004; Sajja and Schein 2004). Under this deﬁ  nition, fully 
40% of patients undergoing laparotomy experience prolonged POI (Delaney 2004). 
Whether or not it is accepted that POI is a mandatory aspect of surgery, surgeons are 
continually trying to ﬁ  nd ways to shorten this period. Traditional methods of providing 
postoperative care have included bowel rest and nasogastric (NG) tube decompression. 
These methods, despite their continued prevalence, have been shown to be ineffective 
and unnecessary and, if anything, increase morbidity (Cheatham et al 1995; Braga 
et al 2002; Nelson et al 2005). Methods for shortening POI target different aspects of 
its multi-factorial etiology.
Prior to 1990, very few articles were published on length of stay issues. None were 
clinical trials or discussed methods to shorten hospital stay. Since 1995, however, 
a plethora of articles has been published which have included randomized, prospective 
studies, and cohort comparison trials. Hospital stay is determined by the need for pain 
control, the presence of nausea and vomiting, fatigue, mechanical factors such as 
surgical drains and stomas, organ dysfunction, and the speed with which diet can be 
advanced. The presence of a postoperative ileus is a major determinant of the length of 
hospital stay. All of these issues have been addressed and methods devised to reduce 
their impact. With nearly 350,000 colorectal and small bowel resections occurring Therapeutics and Clinical Risk Management 2008:4(5) 914
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annually, at an average stay of almost 11 days at a bill to 
the healthcare system of greater than US $20 billion, the cost 
savings could be substantial if length of stay was reduced by 
only 1 to 2 days in each case (Healthcare Costs 2005).
In its simplest form, ileus is deﬁ  ned as the inhibition of pro-
pulsive bowel activity and is manifested by abdominal disten-
tion, nausea, vomiting, and diet intolerance. Of the divisions of 
the gastrointestinal tract, the small intestine resumes its normal 
peristaltic activity within 24 hours, followed by the stomach 
(24–48 hours). The colon can take up to 120 hours for normal 
motility (Miedema and Johnson 2003). The true incidence 
of postoperative ileus is not known because of incomplete 
documentation but is highest in procedures involving small 
bowel and large bowel resections.
The difﬁ  culty in attempting to prevent or relieve POI is in 
part due to an etiology inﬂ  uenced by intrinsic and extrinsic 
mechanisms. Inﬂ  ammatory, hormonal, and pharmacologic 
mechanisms have all been show to play a role in the onset 
of POI. Currently, multi-modal regimens that target multiple 
mechanisms have shown the greatest success in reducing 
POI (Basse et al 2000, 2003; Delaney et al 2001). Those 
by Basse et al suggest that return to bowel function can be 
reduced to 2 days in 90% of patients (Basse et al 2003). 
However, the success of each component of these multimodal 
regimens is limited if narcotics are used for the necessary 
but sometimes detrimental relief of pain. Up until now, there 
has been no pharmaceutical agent that has been consistently 
effective in hastening bowel recovery from abdominal 
surgery. This may change as alvimopan, a peripherally acting 
mu-opioid antagonist, is proving its worth in reducing the 
effects of narcotic medications on bowel motility.
The origins of POI are multifactorial. Basic intestinal 
motility patterns are intrinsically determined by the enteric 
nervous system. Extrinsic control is via the autonomic nervous 
system which can either accelerate or retard these motility 
patterns. Inﬂ  ammatory mediators released in response to 
surgical manipulation, and infection can also affect bowel 
motility. Endogenous and exogenous opioids reduce 
propulsive activity in the gastrointestinal tract. The former 
are released as part of the stress response in the postoperative 
period. Both types of opioids activate the same receptor sites 
in the gut and affect a variety of functions including peristaltic 
activity, secretion, transport of electrolytes and ﬂ  uids, and 
gastric emptying.
Management strategies for POI can be divided into 
prevention and supportive care. For prevention, one can 
alter the choice of anesthesia, the surgical technique, and 
the means of providing pain relief. For supportive care, 
considerable research has looked into avoiding the use of 
routine NG intubation, early ambulation, early oral feeding, 
and prokinetic agents. These strategies have been incorporated 
into fast track protocols designed to shorten POI and hasten 
discharge. For some of these components, evidence is strong 
for their use, for others it is less so. Again, the limiting factor 
seems to be the inhibitory affect of narcotics.
Inﬂ  ammatory
The act of performing a surgical procedure on the bowel 
activates a pro-inflammatory cascade of events within 
intestinal tissues. Latent macrophages become activated 
with bowel manipulation. This increases production of nitric 
oxide (NO), inﬂ  ammatory cytokines and prostaglandins 
via the cyclo-oxygenase-2 pathway (COX-2), all of which 
lead to leukocyte recruitment to the bowel wall. The end 
effect is suppression of bowel muscle function (Bauer and 
Boeckxstaens 2004).
NSAIDS
Changes in the pharmacologic management of patients 
undergoing abdominal surgery have been tried to reduce the 
inﬂ  ammatory component of the procedure and thus POI. With 
the large role the COX-2 pathway plays in the inﬂ  ammatory 
process, it has been hypothesized that use of COX-2 inhibitors 
would help to curb depression of bowel mobility. Results of 
these studies have been mixed, with there either being no 
effect or a slight reduction in POI time. Those studies that 
have shown a beneﬁ  t in using COX-2 inhibitors have not 
been able to demonstrate that the reduction in POI is inde-
pendent of the subsequent reduction in opioid use. The main 
beneﬁ  t of these drugs has been their ability to lower the total 
dose of narcotics needed for adequate pain control (Bouras 
et al 2004; Sim et al 2007). Similar trials have occurred using 
the intravenous anti-inﬂ  ammatory drug, ketorolac. Use of 
ketorolac does have an opioid sparing effect but does little 
to reduce the duration of POI (Chen et al 2005).
Laparoscopy
Numerous studies have shown that laparoscopic surgery 
reduces the duration of POI (Lacy et al 1995; Milsom et al 
1998; Bass et al 2003). The inﬂ  ammatory pathway described 
above was found to increase as surgery progressed and 
early research tried to show that laparoscopic techniques 
would also reduce inﬂ  ammation and thus POI by reducing 
incision size and bowel handling (Kalff et al 1998; Bauer 
and Boeckxstaens 2004). When examined separately, 
incision length and bowel handling could not be shown Therapeutics and Clinical Risk Management 2008:4(5) 915
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to have a measurable effect on POI. Much like the prob-
lems involved in anti-inﬂ  ammatory drug studies, incision 
length studies could not show that reductions of POI seen 
in more minimally invasive surgeries were independent of 
a subsequent decrease in morphine use (Cali et al 1995; 
Delaney 2004).
Hormonal/metabolic
Laparotomy and surgical manipulation of the bowel induces 
a metabolic stress response which stimulates the sympa-
thetic nervous system and adrenergic pathways (Correia 
and da Silva 2004). With this in mind, laboratory trials 
have set out to determine if any medications that block 
these pathways could be effective. Beta-blockers have been 
shown to have no effect on the duration of POI in animal 
models (Bauer and Boeckxstaens 2004; Uemura et al 2004). 
Yohimbine does, however, improve gastrointestinal (GI) 
transit in rats suggesting that the alpha-2 adrenoreceptor is 
the key to the sympathetic response (Uemura et al 2004). 
The anti-acetylcholinesterase effects of neostigmine have 
also been shown to improve symptoms of POI (Bauer and 
Boeckxstaens 2004).
Epidural anesthesia
Another mechanism used to block the influence of 
sympathetic nerves on the gut is thoracic epidural anesthesia. 
Infusion of local anesthetics into the epidural space blocks 
sympathetic stimulation while preserving parasympathetic 
innervation (Fotiadis et al 2004). The GI motility enhancing 
parasympathetic system stems from the vagus nerve whose 
cranial origin is unaffected by epidural anesthesia. This 
theoretical beneﬁ  t ends at the splenic ﬂ  exure after which 
point the colon is controlled by parasympathetic nerves with 
sacral roots. Analysis of the Cochrane database has shown 
a decrease in POI with epidural anesthesia of over 12 hours. 
However, this did not translate into a reduction in LOS 
(Jorgensen et al 2000).
Early nutrition
It has been shown recently that non-pharmacologic 
mechanisms for reducing the stress response are quite 
successful. Early enteral feeding in the immediate post-
operative period is gaining favor as an increasing number 
of studies are showing that it is well tolerated in greater 
than 80% of patients and decreases both POI and LOS 
(Choi and O’Donnell 1996; Velez et al 1997; Stewart 
et al 1998). The theory supporting early feeding is that it 
stimulates gastrointestinal hormones, elicits gut propulsive 
activity, and thus coordinated gut motility. Concern over 
an increased incidence of anastomotic leaks with early 
feeding is unfounded (Correia and da Silva 2004). In fact, 
early feeding reduces the risk of infection and may shorten 
hospital stay. Stimulation of bowel motility without use 
of food has shown some success with gum chewing. The 
chewing serves to act a sham feeding. It is postulated that 
this stimulates the cephalic-vagal reﬂ  ex translating to an 
increase in GI hormone production; time to resolution of POI 
and hospital discharge are both reduced (Asao et al 2002; 
Schuster et al 2006).
Nasogastric decompression
Placement of a NG tube for decompression may alleviate 
symptoms of a POI once they occur. There is no evidence, 
however, that routine placement of a NG tube at surgery 
will prevent an ileus or shorten its duration. They may, in 
fact, increase the incidence of postoperative pulmonary 
complications (Cheatham et al 1995; Nelson et al 2005).
Pharmacologic
To date, pharmacologic agents have had little to no 
effectiveness in minimizing or preventing POI (Bungard and 
Kale-Pradham 1999). Metoclopramide, a dopamine antago-
nist and cholinergic agonist, has not been shown to have a 
beneﬁ  cial affect in most randomized controlled trials (Set 
and Kale-Pradham 2001). Side affects include drowsiness, 
dystonic reactions, and agitation. Cisapride showed modest 
efﬁ  cacy; however, it was withdrawn from the US market 
due to its cardiovascular side affects. Erythromycin, a 
motilin agonist, has not been beneﬁ  cial (Smith et al 2000). 
Antiadrenergic agents block the sympathetic neural reﬂ  ex 
but have little practical use in POI because of potential 
cardiovascular side affects. The same is true for cholinergic 
agents; however, neostigmine has shown some utility in the 
treatment of colonic pseudo-obstruction. Laxatives (stimu-
lant, osmotic, bulking) have not been extensively studied 
in randomized, prospective trials and are not part of most 
fast-track protocols.
Opioids
Many of the previously stated methods to reduce POI are 
confounded by one factor: opioid use. Opioids inhibit 
acetylcholine release, reduce gastrointestinal motility and 
directly lengthen POI with increasing dosages (Cali et al 
1995; Baig and Wexter 2004; Harms and Heise 2007). 
Smaller, laparoscopic incisions, increased use of NSAID 
analgesia and epidural anesthesia, while all theoretically Therapeutics and Clinical Risk Management 2008:4(5) 916
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useful in reducing POI through various mechanisms, are also 
effective reducers of opioid use.
Alvimopan
Alvimopan, a peripherally acting mu-opioid antagonist, 
has recently shown great promise in phase III studies as 
a treatment for POI (Delaney et al 2005). The polarity of 
the alvimopan molecule does not permit it to cross the 
blood–brain barrier. Thus, it does not interfere with centrally 
mediated effects of opioids – including analgesia. It does, 
however, interfere with the peripheral effect of opioids upon 
GI tract motility (Leslie 2005).
Phase III studies have occurred at a number of centers, 
and have studied patients greater than 18 years of age who 
have undergone bowel resection or hysterectomy. Three 
groups were studied: those receiving placebo, 6 mg of 
alvimopan or 12 mg 2 hours before the procedure and up to 
one week after. The primary outcome measure was termed 
GI-3, which was measured at the latter of two events: ﬁ  rst 
toleration of solid food and time to ﬁ  rst ﬂ  atus or bowel 
movement. All of the phase III trials were conducted in 
conjunction with a multi-modal, fast-track treatment regimen 
which included ambulation and ﬂ  uids on POD #1, solids 
on POD #2, morphine PCA, and no postoperative NG tube 
(Tan et al 2007).
Meta analysis of alvimopan phase III trials showed a sig-
niﬁ  cant improvement in time to ﬁ  rst bowel movement, ﬂ  atus, 
and toleration of solid food. Overall, there was a greater than 
12-hour reduction in time to recover GI function (as deﬁ  ned by 
GI-3). Furthermore, there was an improvement in hospital dis-
charge by greater than 16 hours. The placebo and study groups 
showed no difference in overall opioid use or in reported pain 
scores supporting alvimopan’s ability to block the GI but not 
the analgesic effects of narcotic medications. At higher doses 
alvimopan use led to a decrease in nausea and vomiting and 
the need for NG tube insertion. Hospital re-admission was 
lower with alvimopan compared with placebo (Delaney 2004; 
Wolff et al 2004; Delaney et al 2007).
This is a promising result for a condition which has 
resisted all medical management up to this point. It should 
be noted again that all of the phase III trials were conducted 
using a multi-modal, fast-track care path. This resulted 
in a reduced length of stay compared to the average for 
bowel resection in all the groups, including the placebo 
group. This correlates well to the results found by CREAD 
(Controlled Rehabilitation with Early Ambulation and 
Diet) and other multi-modal studies (Delaney et al 2003). 
In addition to early diet and ambulation, CREAD gave 
patients a morphine PCA and ketorolac for pain, no epidural 
anesthesia or NG tube.
Conclusion
If approved for clinical use, phase III studies indicate 
that alvimopan will likely become a useful adjunct to 
postoperative care of patients undergoing colorectal sur-
gery. Until that time multi-modal, fast-track approaches 
hold the greatest promise for POI reduction. As laid out in 
the alvimopan trails, this consists of: no nasogastric tube, 
morphine PCA and ketorolac for pain control, ambulation 
and liquids on POD #1, and solid food on POD #2. This 
regimen reduced length of stay by an average of 5 days, with 
alvimopan further reducing that time by 12 hours or more 
(Delaney et al 2007).
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